Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study

BACKGROUND AND OBJECTIVE: In the randomized controlled trial REMAP-CAP, it was shown that next to dexamethasone, the interleukin (IL)-6 receptor antagonist tocilizumab improves outcome, including survival in intensive care unit (ICU)-admitted coronavirus disease 2019 (COVID)-19 patients. Therefore t...

Descripción completa

Detalles Bibliográficos
Autores principales: Moes, Dirk Jan A. R., van Westerloo, David J., Arend, Sandra M., Swen, Jesse J., de Vries, Annick, Guchelaar, Henk-Jan, Joosten, Simone A., de Boer, Mark G. J., van Gelder, Teun, van Paassen, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502793/
https://www.ncbi.nlm.nih.gov/pubmed/34633645
http://dx.doi.org/10.1007/s40262-021-01074-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502793/
https://www.ncbi.nlm.nih.gov/pubmed/34633645
http://dx.doi.org/10.1007/s40262-021-01074-2

Ejemplares similares